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Abstract 
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine 
disease and associated with insulin resistance. CXC Ligand 5 (CXCL5) is a new 
cytokine which is secreted from white adipose tissue during obesity and by blocking 
insulin signaling pathway inhibits the activity of insulin and promotes insulin 
resistance.  
Objective: The aim of this study was to assess serum level of CXCL5 in PCOS 
women with normal body mass index.  
Materials and Methods: In this case-control study, 30 PCOS women with normal 
body mass index as the case group and 30 non-PCOS women as the controls were 
enrolled. Serum levels of CXCL5, insulin and other hormones factors related with 
PCOS were measured by ELISA method, also the biochemical parameters were 
measured by autoanalyzer. 
Results: Significant increases in serum insulin concentration, homeostasis model 
assessments of insulin resistance, luteinizing hormone, luteinizing hormone/follicle-
stimulating hormone, fasting blood sugar, testosterone, and prolactin were observed 
in the case group compared to the controls. were in the serum level of CXCL5, 
cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-
cholesterol,dehydroepiandrosterone-sulfate, creatinine, and homeostasis model 
assessment of beta cell function between these two groups. 
Conclusion: In this study, no significant change was observed in serum 
concentrations of CXCL5 in PCOS women with normal BMI. 
 
Key words: Polycystic ovary syndrome, Insulin resistance, CXCL5 cytokine, 
Hyperinsulinemia, Hyperandrogenism. 
 
Introduction 
 
olycystic ovary syndrome (PCOS) is 
the most common endocrine disease 
in women (1). The prevalence of 
PCOS in the world is one in every 15 women 
and affects 4-8% of women in the 
reproductive age (2, 3). According to the 
diagnostic criteria of Rotterdam in 2003, 
PCOS women should have at least two of the 
three criteria such as Oligo or anovulation, 
clinical hyperandrogenism and show a 
polycystic ovary on ultrasound (4). This 
disease is characterized by insulin resistance, 
pancreas beta cell dysfunction, impaired 
glucose tolerance, diabetes type II, 
dyslipidemia, and visceral obesity (5, 6).  
Previous studies showed that insulin 
resistance in 50% of women with PCOS is 
related to excessive phosphorylation of serine 
in insulin receptor by the serine/threonine 
kinas enzyme (7, 8). This process can inhibit 
autophosphorylation of tyrosine in insulin 
receptors, without any effect on insulin binding 
leading to insulin resistance in PCOS patients 
(7). This enzyme also increases serine 
phosphorylation of the P450c17 enzyme since 
it is a key enzyme for controlling androgen 
biosynthesis that can lead to increased 
production of androgens (9). As a 
consequence, insulin resistance and 
hyperandrogenism can be seen in PCOS 
women (10, 11). CXC Ligand 5 (CXCL5) is a 
new cytokine which inhibits the activity of 
insulin in muscles and promotes insulin 
resistance and secreted from white adipose 
tissue during obesity (12). This cytokine is 
produced by different cells such as 
monocytes, neutrophils, epithelial cells, 
fibroblasts and smooth muscle cells (13). 
Circulating CXCL5 is highly increased during 
obesity in both mice and humans (14, 15). 
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CXCL5 by blocking insulin signaling pathway 
through activating the pathway of 
Jak2/STAT5/SOCS2, plays an important role 
in the development of insulin resistance (15). 
Following injection of anti-CXCL5 antibody or 
CXCR2 antagonist as CXCL5 receptor, in 
obese mice improves insulin resistance and 
decreases fasting glucose levels (16).  
Due to the positive association of CXCL5 
with insulin resistance and the important role 
of insulin resistance in the pathogenesis of 
PCOS and since this cytokine has been 
studied in obese people so far, we have 
decided to evaluation this cytokine in PCOS 
women with normal body mass index. 
 
Materials and methods 
 
In this case-control study, 30 PCOS 
women with normal body mass index (case 
group) and 30 non- PCOS women with normal 
body mass index (control group) referred to 
the Abolfazle Clinic, dependent to Bushehr 
university of medical scinces, Iran from March 
2015 to September 2016 were enrolled. The 
sample size was obtained with a confidence 
level of 95% and a test power of 80%. 
 
Inclusion and exclusion criteria 
Inclusion criteria in the case group were, 
according to the diagnostic criteria of 
Rotterdam in 2003, PCOS women should 
have at least two of the three criteria covering: 
Oligo or anovulation, clinical 
hyperandrogenism and show a polycystic 
ovary on ultrasound (4).   
Control group were selected from women 
with normal menstruation cycles, normal 
pelvic ultrasound, without acne, as well as 
hirsutism and infertility. 
Both groups had mean body mass index 
(BMI) of 25 kg/m2) and age of 40 yr. All 
women with thyroid disorders, tumors, 
cardiovascular diseases, diabetes mellitus, 
hypertension, renal disorders, and taking 
medications such as contraceptive pills, 
glucocorticoids, or hypertension, estrogenic 
and androgenic drugs in the last three months 
were excluded. 
Sampling and measurement of parameters 
Blood samples from the vein of the right-
arm were obtained in the follicular phase (1st 
to 4th day of menstruation cycle) after 12 h of 
overnight fasting. Serum was obtained after 
centrifugation (3000 rpm for 15 min at 4oC), 
and then the serum was frozen at -80oC. 
Anthropometric parameters including age, 
weight, height, body mass index and waist to 
hip ratio were measured using questionnaires, 
scales and meters. Biochemical parameters 
including fasting blood sugar (FBS), 
Triglyceride  (TG), Cholesterol, High-density 
lipoprotein cholesterol (HDL-C) and creatinine 
(Cr) were measured by autoanalyzer Selectra 
E (Vital scientific N.V, The Netherlands). 
Reliable enzymatic techniques were used for 
measurement of FBS, TG, Cholesterol, Cr, 
Testosterone, Dehydroepiandrosterone-
sulfate) DHEAS) and Prolactin (Pars Azmoon-
co, Iran).  
The HDL-C levels were measured after 
precipitation with magnesium chloride by 
enzymatic techniques (Pars Azmoon-co, Iran) 
and the low-density lipoprotein cholesterol 
(LDL-C) levels were calculated by using the 
Friedwald formula (17). The serum levels of 
insulin and CXCL5 (Crystal Day, China) were 
measured by ELISA technique (Dynex 
Technologies 2cxb3510, USA). Homeostasis 
model assessment of insulin resistance 
(HOMA-IR) and homeostasis model 
assessment of beta-cell function (HOMA-B) 
were calculated by using the following formula 
(18, 19). 
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Ethical consideration 
The research protocol was approved by the 
Ethics Committee of Bushehr University (Id 
number: “IR.BPUMS.AC.REC.1394.100). A 
written informed consent was obtained from 
all participants. 
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Statistical analysis 
We used Statistical Package for the Social 
Sciences (SPSS, version 16.0, SPSS Inc, 
Chicago, Illinois, USA). Independent samples 
t-test and Chi-square test were used to 
compare the quantitative variables in the two 
groups and all the results expressed as 
mean±SD. The single sample Kolmogrov-
Smirnov test was used to estimate the 
variables’ distribution characteristics. p<0.05 
was considered significant. 
 
Results 
 
There were no significant differences in the 
demographic characteristics such as weight, 
height, age, body mass index and the waist- 
hip ratio between case and control groups 
(Table I). There were significant increases in 
serum level of Luteinizing hormone (LH) 
(p=0.004), LH/Follicle-stimulating hormone 
(FSH) (p=0.006), testosterone (p=0.02), and 
prolactin (p=0.04), in the case group 
compared with the controls (Table II). A 
significant increase was observed in 
parameters such as FBS (p=0.01), serum 
insulin level (p=0.04), and HOMA-IR (p=0.04) 
between two groups. Although, serum CXCL5 
level were obtained higher in the case group 
compared to the controls but this difference 
was not significant (Table II). Also, there were 
no significant variations in the amount of TG, 
Chol, HDL-C, LDL-C, FSH, HOMA-B 
Dehydroepiandrosterone-sulfate, and Cr in 
both groups (Table II). 
 
Table I. Demographic characteristics of the two study groups (n=30) 
Characteristic  Control group  Case group p-value 
Age (year)  28.91 ± 8.1 25.85 ± 5.90 0.12 
Weight (Kg)  62.47 ± 15.18 66.74 ± 12.41 0.28 
Height (cm) 161.17 ± 4.71 159.52 ± 6.37 0.30 
BMI (Kg/m2)  24.02 ± 5.60 24.91 ± 3.63 0.40 
waist-hip ratio  0.8 ± 0.07 0.82± 0.06 0.27 
All data presented as Mean ± SD.  Independent samples t test   Chi-square test  BMI: body mass index 
 
Table II. Serum concentrations of variables in patient and control groups (n=30) 
Characteristic Control group  Case group  p- value 
CXCL5 (ng/ml) 378.77 ± 340.57 473.75 ± 436.28 0.30 
Insulin (μIU/ml) 8.76 ± 7.63 16.42 ± 17.01 0.04 
HOMA-IR 2.06 ± 2.04 4.11 ± 4.29 0.04 
HOMA-B 109.50 ± 71.75 179.17 ± 218.82 0.10 
FBS (mg/dl) 91.29 ± 8.53 98.71 ± 11.44 0.01 
Triglyceride (mg/dl) 86.79 ± 50.23 107.04 ± 45.03 0.13 
Cholesterol (mg/dl) 167.83 ± 29.18 175.07 ± 23.32 0.30 
HDL-C (mg/dl) 49.25 ± 12.59 47.92 ± 10.08 0.67 
LDL-C (mg/dl) 100.96 ± 26.55 99.60 ± 25.72 0.62 
LH (mIu/ml) 5.54 ± 2.84 9.46 ± 5.6 0.004 
FSH (mIu/ml) 6.28 ± 2.13 5.24 ± 2.35 0.10 
LH/FSH  1.06 ± 0.84 2.27 ± 1.92 0.006 
Testosterone (ng/ml) 0.71 ± 0.26 0.99 ± 0.52 0.02 
DHEAS (µg/dL) 1.83 ± 0.78 1.99 ± 0.87 0.40 
Prolactin (ng/mL) 15.00 ± 8.84 21.23± 11.94 0.04 
Creatinine (mg/dl) 0.80 ± 0.16 0.81 ± 0.13 0.70 
Data presented as mean±SD. Independent samples t-test, Chi square test, single sample Kolmogrov-Smirnov test. 
CXCL5: CXC Ligand 5 HOMA-IR: Homeostasis model assessments of insulin resistance. 
FBS: Fasting blood sugar  HOMA-B: Homeostasis model assessments of B cell function 
HDL-C: High-density lipoprotein cholesterol LDL-C: Low-density lipoprotein cholesterol 
LH: Luteinizing hormone FSH: Follicle stimulation hormone 
DHEAS: Dehydroepiandrosterone- sufate 
 
Discussion 
 
Our results showed the significant 
increases in serum level of insulin and HOMA-
IR in PCOS women compared with the 
controls. In accordance with these findings, 
Tun and colleagues reported, a significant 
increase in HOMA-IR level in PCOS women 
(20). Also, we showed a significant increase in 
FBS (p =0.01) in PCOS women. In fact, it can 
be stated that insulin sensitivity falls and 
insulin resistance is dominant for 
hyperinsulinemia in PCOS women. Layegh 
and coworkers observed in their study that 
insulin resistance increases in obese (80.3%) 
and non-obese PCOS (72.2%) women (21). In 
our study, a significant increase was observed 
in testosterone level (p=0.02) in the PCOS 
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group compared to the control group. Chen 
and coworkers showed that intra-ovarian 
hyperandrogenism is one of the determining 
factors of follicular arrest in PCOS women. 
Also, it was determined that 
Dihydrotestosterone  suppresses the FSH 
activity in granulosa cells of rats, increases 
accumulation of cells in Gap2/Mitosis phases 
and induces production of a number of large 
arrested follicles. This condition is similar to 
polycystic ovaries for women with PCOS (22). 
Sharquie and colleagues reported that free 
testosterone level can be used as the most 
sensitive biochemical marker in the diagnosis 
of PCOS (23).  
Also, we found the significant increase in 
the level of serum insulin, LH, and LH/FSH 
ratio. Azziz and colleagues showed that 
elevation in the serum levels of LH and insulin 
increase production of ovarian androgens 
synergistically (24). Insulin resistance 
stimulates insulin release, reduces sex 
hormone-binding globulin production and 
increases free testosterone (24, 25). 
Hyperandrogenism and hyperinsulinemia can 
lead to the development of ovarian follicles 
that can cause infertility in PCOS women (24). 
In this study, a significant increase was seen 
in prolactin level (p=0.04) in PCOS women 
compared with the control group. The similar 
results was achieved by Kumar and 
coworkers (26). Nizam and colleagues 
showed that increase in prolactin secretion is 
a major cause of sub-fertility (27). Therefore, 
treatment with drugs that lowered prolactin 
levels resulted in pregnancy for 24% of the 
infertile women (27-30). In a study, Kalsum 
and Jalali found hyperprolactinemia in 69.51% 
of infertile women (31). The results of this 
study showed an increase in CXCL5 level in 
PCOS group compared to the control group 
but this increase was not significant 
statistically; probably it can be attributed to 
low BMI of PCOS women in this study. 
Previous studies have shown that serum level 
of CXCL5 is highly increased during obesity in 
both mice and humans (12, 14, 32).  
Chavey and colleagues reported, in a 
study, a significant increase in serum level of 
CXCL5 in obese French people compared to 
lean French people (12). Also, they showed a 
significant positive correlation between serum 
level of CXCL5 and body weight in the French 
population and reported that inhibition of 
CXCL5 secretion in obese people can reduce 
the risk of developing obesity-related 
pathogenesis. So, inhibition of CXCL5 
signaling can be used as a therapeutic 
modality for metabolic syndrome (12). On the 
other hand, Layegh and coworkers while 
assessing endocrine-metabolic disorders and 
insulin resistance in obese PCOS women 
(BMI >25), and non-obese ones (BMI <25), 
stated that metabolic abnormalities in obese 
PCOS women are more common than non-
obese PCOS women. As, in 39.4% of obese 
PCOS women, metabolic syndrome was 
observed while no case of metabolic 
syndrome was seen in non-obese PCOS 
women (21). Thus, the serum level of CXCL5 
increases with weight gain and obesity. It can 
be stated that probably CXCL5 in obese 
PCOS women can be effective in causing 
metabolic disorders associated with PCOS. 
 
Conclusion 
 
In this study, no significant change was 
observed in serum concentrations of CXCL5 
in PCOS women with normal BMI. 
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